Investment analysts at MLV & Co assumed coverage on shares of Avanir Pharmaceuticals (NASDAQ: AVNR) in a note issued to investors on Friday. They set a “buy” rating and a $6.00 price target on the stock.
Separately, analysts at Canaccord Genuity reiterated a “buy” rating on shares of Avanir Pharmaceuticals in a research note to investors on Tuesday, December 13rd. Analysts at Jefferies Group (NYSE: JEF) reiterated a “hold” rating on shares of Avanir Pharmaceuticals in a research note to investors on Tuesday, December 13rd. They now have a $3.00 price target on the stock, down previously from $3.50.
AVANIR Pharmaceuticals, Inc. (AVANIR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company focuses on products for the central nervous system. It also has a number of partnered programs in other therapeutic areas. Its docosanol 10% cream, sold in the United States and Canada as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare, is the only over-the-counter treatment for cold sores that has been approved by the United Sates Food and Drug Administration (FDA). In October 2010, FDA approved NUEDEXTA, is a combination of dextromethorphan/quinidine, for the treatment of pseudobulbar affect (PBA).
Shares of Avanir Pharmaceuticals opened at 2.87 on Friday. Avanir Pharmaceuticals has a one year low of $1.77 and a one year high of $4.80. The stock’s 50-day moving average is $2.23 and its 200-day moving average is $2.80. The company’s market cap is $364.4 million.